Home / VEGF / Recombinant Human VEGF 189 (aa 27-215) Protein

Recombinant Human VEGF 189 (aa 27-215) Protein

Catalog #: 8147-VE
2 Citations Datasheet / COA / SDS

Carrier Free

Catalog # Availability Size / Price Qty
8147-VE-025/CF

With Carrier

Catalog # Availability Size / Price Qty
8147-VE-025
Best Seller
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (2)
FAQs
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGF 189 (aa 27-215) Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE with silver staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 4-40 ng/mL.
Source
Chinese Hamster Ovary cell line, CHO-derived human VEGF protein
Ala27-Arg215
Accession #
AAA36804
N-terminal Sequence
Analysis
Ala27
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
22 kDa (monomer)
SDS-PAGE
22-30 kDa, reducing conditions

Product Datasheets

You must select a language.

x

8147-VE (with carrier)

Product Datasheet
COA
SDS

You must select a language.

x

8147-VE/CF (carrier free)

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

8147-VE

Formulation Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Reconstitution Reconstitute at 500 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

8147-VE/CF

Formulation Lyophilized from a 0.2 μm filtered solution in HCl.
Reconstitution Reconstitute at 500 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGF

VEGF189 (Vascular Endothelial Growth Factor-A of 189 amino acids) is a 50-52 kDa homodimeric glycoprotein member of the PDGF/VEGF family of molecules (1, 2). A large number of human VEGF isoforms are generated by alternative splicing, including VEGF189 which lacks amino acids (aa) 166-182 of the full length protein (VEGF206) (3-5). Mature human VEGF189 shares 88% aa sequence identity with mouse VEGF188. VEGF189 binds to heparan sulfate both on the cell surface and in the extracellular matrix (ECM) where it retains bioactivity (6, 7). It can undergo proteolytic cleavage from the ECM (at Arg136-Ala137), creating a soluble fragment with increased bioactivity (6, 7). VEGF189 is widely expressed including by vascular smooth muscle cells (3), chondrocytes (8), fibroblasts (9), neuronal and glial cells (10), and neutrophils (11). VEGF189 interacts with various receptors including VEGF R1, VEGF R2, Neuropilin-1, and Integrins aVb3, aVb5, a3b1, and a5b1 (6, 12-14). VEGF189 exerts complex effects in angiogenesis. It is proapoptotic towards quiescent vascular endothelium but is proangiogenic towards endothelium that has committed to the angiogenic process (6, 14). In particular, venous endothelial cells are highly responsive towards VEGF189, while the responsiveness of arterial endothelium is primarily restricted to the regulation of migration (7). In addition to its vascular effects,  immobilized VEGF189 serves as an anchor for cells expressing Integrin avb3, and it acts as both a chemotactic and chemokinetic factor for migrating neutrophils (11, 13, 14).

References
  1. Woolard, J. et al. (2009) Microcirculation 16:572.
  2. Ferrara, N. et al. (2003) Nat. Med. 9:669.
  3. Tischer, E. et al. (1991) J. Biol. Chem. 266:11947.
  4. Leung, D.W. et al. (1989) Science 246:1306.
  5. Keck, P.J. et al. (1989) Science 246:1309.
  6. Plouet, J. et al. (1997) J. Biol. Chem. 272:13390.
  7. Herve, M-A. et al. (2005) Exp. Cell Res. 309:24.
  8. Cramer, T. et al. (2004) Osteoarthritis Cartilage 12:433.
  9. Detmar, M. et al. (1997) J. Invest. Dermatol. 108:263.
  10. Tang, H. et al. (2013) Neurobiol. Aging 34:1412.
  11. Houck, K.A. et al. (1992) J. Biol. Chem. 267:26031.
  12. Herve, M-A. et al. (2008) Am. J. Pathol. 172:167.
  13. Hutchings, H. et al. (2003) FASEB J. 17:1520.
  14. Vintonenko, N. et al. (2011) Cell Adh. Migr. 5:332.
Long Name
Vascular Endothelial Growth Factor
Entrez Gene IDs
7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
Alternate Names
MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor

Citations for Recombinant Human VEGF 189 (aa 27-215) Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

2 Citations: Showing 1 - 2
Filter your results:

Filter by:

  1. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance
    Authors: S Ma, LS Mangala, W Hu, E Bayaktar, A Yokoi, W Hu, S Pradeep, S Lee, PD Piehowski, A Villar-Pra, SY Wu, MH McGuire, OD Lara, C Rodriguez-, CJ LaFargue, NB Jennings, KD Rodland, T Liu, V Kundra, PT Ram, S Ramakrishn, G Lopez-Bere, RL Coleman, AK Sood
    Cell Reports, 2021-08-17;36(7):109549.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Cross-activating c-Met/?1 integrin complex drives metastasis and invasive resistance in cancer
    Authors: A Jahangiri, A Nguyen, A Chandra, MK Sidorov, G Yagnik, J Rick, SW Han, W Chen, PM Flanigan, D Schneidman, S Mascharak, M De Lay, B Imber, CC Park, K Matsumoto, K Lu, G Bergers, A Sali, WA Weiss, MK Aghi
    Proc. Natl. Acad. Sci. U.S.A., 2017-09-26;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human VEGF 189 (aa 27-215) Protein

There are currently no reviews for this product. Be the first to review Recombinant Human VEGF 189 (aa 27-215) Protein and earn rewards!

Have you used Recombinant Human VEGF 189 (aa 27-215) Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review